|
|
Innate immune regulation of neuroinflammation |
| 5R01AI162936-02 |
|
NIAID |
2022 |
|
|
The Impact of Maternal CMV Infection on Birth Outcomes |
| 5R03AI151426-02 |
|
NIAID |
2022 |
|
|
Discovery of novel smHDAC8 inhibitors for the treatment of schistosomiasis |
| 5R21AI146512-02 |
|
NIAID |
2022 |
|
|
Immunoregulatory effect of microparticle delivered STING agonist in the control of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS) |
| 5R21AI154772-02 |
|
NIAID |
2022 |
|
|
Role of B cell interactions in CNS autoimmune demyelination |
| 5R21AI156123-02 |
|
NIAID |
2022 |
|
|
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasis |
| 5R21AI156554-02 |
|
NIAID |
2022 |
|
|
The effects of BTNL2 on experimental autoimmune encephalomyelitis |
| 5R21AI156779-02 |
|
NIAID |
2022 |
|
|
A Non-Viral Genetic Vaccine for Prevention and Treatment of Multiple Sclerosis |
| 5R21AI160738-02 |
|
NIAID |
2022 |
|
|
Role of IFNs and IFNGR in susceptibility to bacteria in Down syndrome |
| 5R21AI161827-02 |
|
NIAID |
2022 |
|
|
Function of TCF-1 in antagonizing malignancy |
| 5R21AI163256-02 |
|
NIAID |
2022 |
